Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 14Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Thoracic 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 109Uterine Cervical Neoplasms 57Endometrial Neoplasms 38Fallopian Tube Neoplasms 34Carcinoma, Ovarian Epithelial 27Breast Neoplasms 25Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 12Uterine Cervical Dysplasia 11Recurrence 11Stomach Neoplasms 10Neoplasm Metastasis 10Lung Neoplasms 9Colorectal Neoplasms 9Uterine Neoplasms 8Triple Negative Breast Neoplasms 8Sarcoma 8Urinary Bladder Neoplasms 7Melanoma 6Esophageal Neoplasms 6Vulvar Neoplasms 5Vaginal Neoplasms 5Testicular Neoplasms 5Lymphoma, Non-Hodgkin 5Small Cell Lung Carcinoma 4Sezary Syndrome 4Rectal Neoplasms 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4

Interventions

Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liposarcoma × Gynecologic × Clear all
NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡